Results 61 to 70 of about 1,057,002 (233)
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778) +11 more
core +1 more source
Identification of mimotopes for the H4 minor histocompatibility antigen [PDF]
The H4 minor histocompatibility antigen (HA) of mice includes a single immunogenic peptide presented by H-2Kb molecules that stimulates skin allograft rejection and is immunodominant in the stimulation of cytolytic T lymphocytes (CTL) specific for multiple minor HA.
Strausbauch, M A +4 more
openaire +2 more sources
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
Characterization and recognition of minor histocompatibility antigens [PDF]
Minor histocompatibility antigens (MiHA) are structures that can be recognized by T cells. In the setting of allogeneic stem cell transplantation MiHA presented by patient cells can be recognized by donor T cells.
Bergen, Cornelis Adrianus Maria van
core
Description of Experimental BMT Model.
MHC – Major histocompatibility complex.MiHAs – Minor histocompatibility antigens.
Alicia Zhou (523846) +8 more
core +1 more source
Composition of allogeneic equine orthobiologics and their repeated intra‐articular administrations
Abstract Background Orthobiologics such as platelet‐rich plasma (PRP) and alpha‐2‐macroglobulin (A2MG) are increasingly used for equine musculoskeletal injuries. However, their composition and safety with repeated allogeneic intra‐articular administration remain poorly investigated.
Yanne Van Reusel +7 more
wiley +1 more source
What are minor histocompatibility loci? A new look at an old question.
In this article, Derry Roopenian relates the traditional view of minor histocompatibility (H) loci to recent advances in understanding of the tissue rejection process and the molecular nature of minor histocompatibility antigens.
Roopenian, D C
core +1 more source
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is routinely used to treat hematopoietic malignancies. The eradication of residual tumor cells during engraftment is mediated by donor cytotoxic T lymphocytes reactive to alloantigens.
Nadia A. Bykova +2 more
doaj +1 more source
Patients undergoing allogeneic stem cell transplantation as treatment for hematological diseases face the risk of Graft-versus-Host Disease as well as relapse. Graft-versus-Host Disease and the favorable Graft-versus-Leukemia effect are mediated by donor
J. H. Frederik Falkenburg (8558778) +11 more
core +1 more source
High-throughput minor histocompatibility antigen prediction [PDF]
Abstract Motivation: Minor histocompatibility antigens (mHags) are a diverse collection of MHC-bound peptides that have immunological implications in the context of allogeneic transplantation because of their differential presence in donor and host, and thus play a critical role in the induction of the detrimental graft-versus-host ...
David S. DeLuca +4 more
openaire +2 more sources

